Performance of next-generation molecular methods in the diagnosis of pleural space infections and their aetiology

Authors

Peter T. Bell[1,2,3 #], Timothy Baird[1,2,4 #], John Goddard[1,5], Olusola S. Olagoke[2,4], Andrew Burke[3,6], Shradha Subedi[2,7], Tiana R. Davey[2,4], James Anderson[1,5], Derek S. Sarovich[2,4 ^], and Erin P. Price[2,4 ^*]

[#,^] Authors contributed equally

Affiliations

[1]Department of Respiratory Medicine, Sunshine Coast University Hospital, Birtinya, Queensland, Australia

[2]Sunshine Coast Health Institute, Birtinya, Queensland, Australia

[3]School of Medicine, University of Queensland, Herston, Queensland, Australia

[4]Centre for Bioinnovation, University of the Sunshine Coast, Sippy Downs, Queensland, Australia

[5]School of Medicine and Dentistry, Griffith University, Sunshine Coast, Queensland, Australia

[6]Department of Infectious Diseases, The Prince Charles Hospital, Chermside, Queensland, Australia

[7]Department of Infectious Diseases, Sunshine Coast University Hospital, Birtinya, Queensland, Australia

***Corresponding Author**

Erin P. Price

University of Sunshine Coast

eprice@usc.edu.au

+61 7 54565568

Keywords: empyema; metagenomics; high-throughput sequencing; 16S rRNA; metataxonomics; parapneumonic effusion; pleural infection; conventional culture; diagnostics

Abstract

Pleural space infections (PSIs) are common and associated with substantial healthcare cost, morbidity, and mortality. Accurate PSI diagnosis remains challenging due to low culture positivity rates, frequent polymicrobial involvement, and non-specific diagnostic biomarkers. To better understand the comparative diagnostic yield of culture-independent technologies for PSI diagnosis, we prospectively characterised 26 clinically suspected PSIs and 10 control patients with non-infective pleural effusions using shotgun metagenomics, bacterial metataxonomics, quantitative PCR, and conventional culture. We demonstrate that culture-independent molecular techniques have superior sensitivity and negative predictive values for PSI diagnosis compared with conventional culture. Bacterial metataxonomics and metagenomics were both sensitive to the detection of polymicrobial infections, and unveiled microbial heterogeneity. Metagenomics also detected fungi and DNA viruses within pleural fluid. Dominant pathogens in the PSI cohort according to the highest resolution method, metagenomics, included streptococci (*S. intermedius*, *S. pyogenes*, *S. mitis*), *Prevotella* spp. (*P. oris*, *P. pleuritidis*), staphylococci (*S. aureus*, *S. saprophyticus*), and *Klebsiella pneumoniae.* Taken together, these results demonstrate the potential utility of molecular methods in the accurate diagnosis of PSI, which represents an important step towards improving personalised treatment decision-making and antimicrobial stewardship in suspected PSI.

Introduction

Pleural space infection (PSI) is a complex, heterogeneous, and challenging clinical entity associated with prolonged hospitalization, significant healthcare costs, morbidity and mortality [1-4]. Frustrations in the clinical management of suspected PSI arise due to limitations in culture-based microbiologic diagnostics, which are notoriously insensitive (culture-positive rates of only 20-40% [5-8]), resulting in prolonged and potentially inappropriate broad-spectrum antimicrobial use. Culture-based diagnostic sensitivity in PSI is poor due to multiple factors, including prompt institution of empiric antibiotics prior to pleural sampling, low pathogen concentration in pleural fluid, and difficulties in cultivating fastidious microorganisms [4,9]. Limitations in culture-based diagnostics have obscured characterization of the complete pleural space 'microbiome' (i.e. the microbial communities present in clinical specimens), hampering clinical progress [10].

Molecular diagnostic approaches enable culture-independent microbial identification from complex niches such as clinical specimens [11]. Such molecular techniques include shotgun metagenomics, metataxonomics, and quantitative PCR (qPCR). Shotgun metagenomics involves DNA sequencing of genomes and genes from all microbiota (excluding RNA viruses), followed by mapping to a reference microbial genome database, allowing strain-level detection of all bacteria, archaea, fungi, and DNA viruses in a sample, along with determining their putative functions (e.g. resistance and virulence genes). Metataxonomics involves high-throughput amplicon sequencing of the bacterial 16S ribosomal RNA (16S rRNA) or fungal internal transcriber spacer (ITS) regions to characterize entire bacterial or fungal microbiota, respectively, in a given sample; these methods typically resolve microbiota to the genus level. qPCR is a rapid and inexpensive same-day diagnostic method that specifically amplifies target taxa of interest, with resolution ranging from strain to domain level, the latter of which involves targeting the 16S or ITS regions to quantify only total bacterial or fungal load within a given sample [12,13].

Several recent studies applying culture-independent techniques have revealed improved diagnostic yield, and a previously untapped PSI microbiome, confirming that, in many cases, PSI is a polymicrobial disease with a diverse range of co-aggregating pathogens [7,8,14 15]. Complex symbiotic interactions and cross-talk between and among microbes may therefore play an important role in PSI development, natural history, response to treatment, and prognosis [8].

To better understand the comparative diagnostic yield and clinical value of culture-independent technologies in PSI diagnosis, we performed a prospective observational single-center study of 26 consecutive patients presenting with suspected PSI at an Australian hospital, and 10 consecutive control patients lacking clinical suspicion of PSI. We then compared the diagnostic performance and resolution of microbe-enriched shotgun metagenomics, bacterial metataxonomics, panbacterial qPCR, and panfungal qPCR with conventional culture.

Methods

Ethics Statement. The study was approved by The Prince Charles Hospital (TPCH) Human Research Ethics Committee (HREC) HREC/2022/QPCH/81858 and the Sunshine Coast Hospital and Health Service Research Governance Office. All participants provided written informed consent. Patient IDs are coded and only re-identifiable by members of the research clinical team.

Study Participants. All patients ≥18 years of age presenting with suspected PSI (denoted with a '-P' suffix) admitted between March and November 2022 to the Sunshine Coast University Hospital (SCUH), Queensland, Australia, were prospectively invited to participate in this study. Suspected PSI, as determined by a specialist respiratory physician, was based on a supportive clinical history (e.g., fever, pleuritic chest pain), imaging evidence of pleural infection (pleural fluid loculation/septation on ultrasound and/or computed tomography), and/or biochemical evidence of infection (elevated white cell with left shift and elevated C-reactive protein [CRP]). Individuals undergoing a diagnostic and/or therapeutic procedure for suspected PSI were invited to participate. Based on these criteria, 26 consecutive patients with 'clinically suspected PSI' (see: '*Definition of Diagnostic Reference Standard*' below) were recruited to the study.

For the control group, patients with pleural effusion without clinical suspicion for PSI (e.g., malignancy or heart failure) at the time of pleural sampling (denoted with a '-C' suffix) were enrolled. These individuals were approached if they had an alternative effusion cause, absence of clinical history to support active infection, and simple effusion appearance on ultrasound and/or computed tomography. Patients were excluded if they had prior sampling of the pleural space, any clinical concern for current or recent infection, concomitant abdominal ascites, hepatic hydrothorax, or antibiotic administration within 3 weeks of pleural sampling. Ten participants meeting these criteria were enrolled.

Specimen Collection, Storage, and Processing. For the PSI cohort, specimens were collected as soon as practicable from the time of admission to hospital. Antibiotic commencement ranged from 21 days prior to pleural sampling through to the time immediately post-pleural aspiration (*Table S1*). Between 10 and 60 mL pleural fluid was collected into two sterile specimen pots at the time of diagnostic pleural sampling using aseptic conditions. One pot was immediately mixed with 7mL RNA stabilization agent [16] for total DNA extraction (bacterial metataxonomics and qPCR); the second pot contained only pleural fluid for culture and host DNA depletion and extraction (metagenomics). Specimens were immediately stored at 4°C until processed. In parallel, specimens were also collected for routine microscopy (cell count, white blood cell differential, Gram stain), and biochemistry analyses (pleural fluid pH, protein, glucose, lactate dehydrogenase).

Microbial culturing was undertaken by both SCUH's onsite Pathology laboratory and by our Research laboratory, with matrix-assisted laser desorption ionization time-of-flight mass spectrometry (bioMérieux, North Ryde, NSW, Australia) or Illumina NovaSeq 6000 whole-genome sequencing

(WGS; Australian Centre for Ecogenomics, St Lucia, QLD, Australia) used respectively to confirm species identity. 16S rRNA (i.e. bacterial) metataxonomic sequencing was carried out using V3-V4 amplification [17], followed by Illumina MiSeq 300bp paired-end sequencing (Ramaciotti Centre for Genomics, Sydney, NSW, Australia). Metagenomic sequencing on host-depleted DNA was performed using Illumina NovaSeq 6000 150bp paired-end reads (17-27 million reads/sample; Azenta Life Sciences, Suzhou, China). For qPCR analyses, total genomic DNA was tested against panbacterial (16S rRNA) [18], panfungal (28S rRNA) [19], and human (β-globin) [20] qPCR assays to quantify microbial-to-host load. For the panbacterial qPCR assay, a cycles-to-threshold (C_T) cut-off value of 31 was used to delineate PSI-positive vs. PSI-negative cases. Further methodological details are described in *Supplementary Material – 'Methods'.*

Definition of Diagnostic Reference Standard. Due to the lack of an optimal 'gold-standard' test for PSI confirmation, 'clinical likelihood of PSI' was objectively stratified using predefined clinical criteria:

1. *Definite/Probable PSI*: (i) clinical evidence of PSI as assessed by the recruiting physician based on fever, elevated white cell count, presence of pleurisy, raised inflammatory markers, and suitable clinical presentation; AND (ii) either direct evidence of PSI defined as the presence of Gram stain and/or culture positive on pleural fluid; OR indirect evidence of PSI based upon pleural fluid pH < 7.2 as measured on a blood gas analyser and/or glucose <3.0 mmol/L AND (iii) accompanied by at least two of the following criteria: serum CRP > 100 mg/L; complex pleural fluid on imaging; fever (> 38.0^{o}C). 2. *Possible PSI:* (i) clinical evidence of PSI (as defined in (i) above), AND (ii) negative Gram stain and culture negative on pleural fluid AND pH ≥ 7.2 and glucose >3.0 mmol/L) AND (iii) accompanied by at least 2 of the following criteria: CRP > 100 mg/L; complex (i.e. loculated) pleural fluid collection on imaging; fever (≥ 38.0 ^{o}C). 3*. Unlikely PSI:* (i) No clinical evidence of PSI, AND (ii) all of the following criteria are met: pleural fluid Gram stain and culture negative with pH ≥ 7.2, glucose >3.0 mmol/L, serum CRP < 100 mg/L, uncomplicated effusion on CT and or ultrasonographic imaging, and an alternate diagnosis confirmed (i.e. heart failure, malignancy).

Statistical Analyses. To determine diagnostic test performance, '*Definite/Probable PSI'* was used as the PSI-positive reference. Specificity, sensitivity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for microbial culture and the three molecular methods (qPCR, bacterial metataxonomics, metagenomics). Additionally, Spearman's Rho was used to determine PSI/non-PSI diagnostic correlations between the four testing methods.

Results

Study participants and clinical outcomes

Twenty-six patients (*n*=7 female; median age of 67 years [range 20 – 95]) with suspected PSI had an exudative pleural effusion as defined by Light's criteria [21]. Twenty-four (92%) had loculated (complex) pleural effusions on ultrasound and/or computed tomography imaging, with 20 patients (77%) also having associated lung consolidation at the time of cross-sectional imaging. Among the 10 control subjects, 9 were diagnosed with malignant pleural effusion (MPE), and one with decompensated congestive heart failure (Table 1).

Twenty-five patients (96%) with suspected PSI underwent intercostal catheter insertion, whereas one underwent diagnostic/therapeutic needle aspiration alone. All suspected PSI patients received broad-spectrum antimicrobial therapy (*Table S1*). Intrapleural enzyme therapy (5mg DNase and 10 mg tissue plasminogen activator) was administered in 17 patients (65%) with suspected PSI, and four patients (15%) required surgical decortication (Table 1). Thirty-day mortality within the suspected PSI cohort was 12% (*n*=3).

Test Performance across diagnostic methods

Conventional culture. Pathology lab testing returned 10 (38%) microbial culture-positive results from the PSI cohort (Table 2). Six (23%) were culture-positive from Research lab testing, with 100% overlap with the Pathology results.

qPCR. Positive bacterial detection was achieved with panbacterial qPCR in 14/26 (54%) suspect PSI cases (Table 2). All panbacterial qPCR-positive results were also PSI-positive by metagenomics and/or bacterial metataxonomics (Table 2). Panfungal qPCR did not identify fungi in any PSI or control specimens.

Bacterial metataxonomics and shotgun metagenomics. Together, bacterial metataxonomics and metagenomics identified 16/26 (62%) suspect PSI cases as PSI-positive, with 14/26 (54%) cases determined by each individual method. Metagenomics identified 7/14 (50%) cases as polymicrobial, whereas bacterial metataxonomics identified 5/14 (36%) cases as polymicrobial (Table 2 & Figure 1). Despite both methods identifying 14 PSI cases each, only 12 cases were identified as PSI by both methods, of which three were polymicrobial by both methods (Table 2). Far fewer taxa were identified by bacterial metataxonomics in two polymicrobial cases (SCHI0131-P, SCHI0172-P) (Table 2).

Molecular diagnostics vs microbial culture. When compared against our 'PSI-positive' reference classification (Table 1), all molecular diagnostic methods demonstrated superior sensitivity and NPVs compared with microbial culture (Table 3). As expected, specificity and PPVs remained high across all diagnostic methods.

Using Spearman's rank correlation (r_s) to examine the relationship between PSI diagnostic methods (Figure 3), conventional culture was less strongly correlated with molecular methods (metagenomics: r_s=0.56 (p<0.001); bacterial metataxonomics: r_s=0.39 (p=0.05); panbacterial qPCR: r_s=0.39 (p=0.05)). Metagenomics demonstrated the strongest correlation across methods (bacterial metataxonomics: r_s=0.69 (p<0.001); panbacterial qPCR: r_s=0.69 (p<0.001); conventional culture: r_s=0.56 (p<0.01)). The strongest individual correlation was between panbacterial qPCR and bacterial metataxonomics (r_s=0.85; p<0.001; Figure 3); this result was expected as both methods target the same gene.

PSI microbial aetiology

A diverse array of naso-oropharyngeal-, respiratory tract-, and gut-associated microbes were detected in the 14 metagenomic PSI-positive specimens (Table 2 & Figure 1). The most common dominant organisms were *Streptococcus* spp. (n=5; 2 x *S. intermedius*, 2 x *S. pyogenes*, 1 x *S. mitis*), followed by *Prevotella* spp. (n=2; *P. oris*, *P. pleuritidis*), *Staphylococcus* spp. (n=2; *S. aureus*, *S. saprophyticus*), and *Klebsiella pneumoniae* (n=2) (Table 2). Seven (50%) metagenomic PSI-confirmed cases were identified as monomicrobial, of which two harboured *S. intermedius*, along with one each of *K. pneumoniae*, *S. saprophyticus*, *S. aureus*, *Enterococcus faecium*, and *Escherichia coli* (Table 2 & Figure 2). In contrast, bacterial metataxonomics identified nine (35%) monomicrobial PSI cases, of which four were *Streptococcus* sp., vs. one each of *Escherichia-Shigella* sp., *Fusobacterium* sp., *Haemophilus* sp., *Klebsiella* sp., and *Prevotella* sp. (Table 2 & Figure 2). Five monomicrobial cases overlapped with the two meta-omics methods; however, bacterial metataxonomics erroneously assigned two monomicrobial PSI cases, SCHI0132-P and SCHI0143-P, as '*Streptococcus*', despite the SCHI0132-P isolate being confirmed as coagulase-negative *Staphylococcus* sp. by MALDI-TOF testing (Table 2), indicating a probable bacterial metataxonomic database error for this genus.

As expected, bacterial metataxonomics failed to identify fungi or viruses in the PSI cases, whereas conventional culture (followed by WGS) and metagenomics identified *P. kudriavzevii* in SCHI0131-P. Metagenomics further identified *Rhizoctonia solani*, *Wallemia mellicola*, *Meyerozyma guilliermondii*, *Truncatella angustata*, *Cokeromyces recurvatus*, *Bipolaris maydis*, *Candida orthopsilosis*, and *Gilbertella persicaria* in SCHI0131-P (subject suffered from confirmed Boorhaaves syndrome), *Candida dubliniensis* in SCHI0140-P, and *Candida tropicalis*, *Fonsecaea pedrosoi*, and *Pyricularia pennisetigena* in SCHI0125-P. In all instances, fungal taxa were in relatively low abundance in the metagenomic data. Metagenomics also identified bacteriophages in 5/26 PSI-positive cases, with *Staphylococcus* phage Andhra seen in SCHI0123-P, SCHI0125-P, SCHI0127-P, and SCHI0128-P, and *Streptococcus* phage SM1 seen in SCHI0131-P. *Staphylococcus* phage Andhra was among the most dominant taxa seen in SCHI0125-P and SCHI0128-P, indicating very high phage levels in pleural fluid. Both of these specimens harboured *S. aureus* according to metagenomics, and SCHI0125-P also had *S. saprophyticus* according to culture and WGS (Table 2 & Figure 2).

Pleural fluid from two non-PSI control participants, SCHI0152-C and SCHI0175-C, unexpectedly cultured *Candida parapsilosis* and *Moraxella osloensis*, respectively, in the Research lab. These

isolates were confirmed by WGS. Metagenomics also unexpectedly found microbes in 2/10 control cases (Table 2). The non-pathogenic single-stranded DNA virus, adeno-associated dependoparvovirus A, was identified in SCHI0173-C, and *M. osloensis* was confirmed in SCHI0175-C. The culture- and WGS-confirmed *C. parapsilosis* isolate retrieved from SCHI0152-C was not detected by metagenomics, suggesting possible operator contamination during specimen collection or processing. Bacterial metataxonomics failed to identify the culture-confirmed *M. osloensis* in SCHI0175-C, but identified *Escherichia-Shigella* in SCHI0152-C (1453 reads) and *Corynebacterium* in SCHI0173-C (190 reads), findings that were not supported by the other methods, again likely due to contamination.

Microbiology and clinical outcomes

Of the three PSI cases with a < 30-day mortality, two (SCHI0128-P and SCHI0134-P) were infected with *K. pneumoniae*, and two (SCHI0131-P and SCHI0128-P) had polymicrobial infections according to metagenomics. In contrast, no patient surviving beyond 30 days (*n*=23) harbored *Klebsiella* spp. according to any testing method.

Antimicrobial resistance gene detection

In silico antimicrobial resistance gene detection only identified innate drug resistance genes, with no evidence of acquired drug resistance development in any case (*Table S1*).

Discussion

Clinical decision-making in suspected PSI cases is challenging, predominantly due to low culture positivity rates [5-8], resulting in frequent diagnostic uncertainty and antimicrobial overuse. Patients with culture-positive PSI exhibit more severe disease and higher mortality [3]; understanding PSI microbiome composition thus plays a critically important role in improving patient prognosis. Recent work [7,8,14,15] has highlighted the potential advantages of applying culture-independent molecular methods in PSI diagnostics. To this end, we performed a pragmatic, single-centre, prospective study of individuals with clinician-suspected PSI to better understand the comparative diagnostic yield and clinical value of culture-independent technologies. Confirming these prior studies, we demonstrate that all three culture-independent molecular techniques are superior to currently used conventional culture for PSI diagnosis and aetiologic confirmation. Furthermore, metagenomics and bacterial metataxonomics unveiled greater microbial heterogeneity than could be detected by the other methods.

The advent of metataxonomics and shotgun metagenomics has facilitated comprehensive microbiome characterisation in myriad human diseases. In line with recent PSI molecular studies [8,15], we confirm that PSIs can be caused by either single or multiple pathogens. The pleural microbiome in our cohort was frequently characterised by naso-oropharyngeal-colonising bacteria including streptococci (*S. intermedius*, *S. pyogenes*, *S. mitis*), staphylococci *(S. aureus*, *S. saprophyticus),* and the anaerobic *Prevotella* spp. (*P. oris*, *P. pleuritidis*), with occasional occurrence of lower respiratory or gut tract flora (*E. coli*, *E. faecium*, *K. pneumoniae*) (Table 2). Similar to recent work published from China [15], we observed that polymicrobial bacterial infection was also occasionally associated with fungal coinfection using metagenomics, confirming the extremely challenging nature of treating complex polymicrobial PSIs across microbial domains. Streptococcal and staphylococcal phages were also seen in five PSI cases, with their host species not always detected, suggesting possible lytic activity towards their host within the pleural space, or incidental phage transit from other body sites [22]. Although not examined here, others have shown that phage presence in clinical specimens can negatively impact culture rates [23]. Finally, we found that *K. pneumoniae* presence was associated with mortality, consistent with recent bacterial metataxonomic data showing an association between Enterobacteriaceae and PSI mortality [8].

Prior studies [7,8,14] of the pleural space microbiome have identified 100% PSI positivity using molecular testing. In contrast, only 62% PSI-positive cases were identified in our study. Our lower positivity rate likely reflects our study design, which, unlike most earlier studies [7,8,14], prospectively recruited consecutive patients with suspected PSI without prior knowledge of pleural fluid biochemistry or microbiology. This study design thus aimed to capture a more accurate representation of the diagnostic uncertainty facing clinicians in real-world practice. To our knowledge, only one other study has not used prior knowledge of pleural fluid biochemistry or microbiology for molecular PSI identification and characterisation; their PSI positivity rate was 70% [15]. Lower 'real world' PSI-positive rates suggest that a subset of patients with clinically suspected PSI and/or para-pneumonic effusions

have no pleural microbial biomass at time of sampling (38% in this study), even with highly sensitive deep sequencing methodologies. We suspect that many, or all, of these patients may truly have non-infective parapneumonic effusions – a conclusion further supported by their more benign pleural biochemistry using recognised cut-off values (i.e. pH < 7.2; glucose <3.0 mmol/L) [1]. These collective data suggest that molecular testing could play an important role in clinical practice, particularly as an adjunct to current PSI diagnostics, thereby reducing empiric antimicrobial burden, duration, and spectrum in pleural effusion cases. In particular, we and others [24] have shown that panbacterial qPCR stands out as a cost-effective, simple, and rapid (same-day) diagnostic screening tool that could be readily implemented in clinical practice; its routine use on pleural fluid specimens would assist with both antimicrobial stewardship efforts and treatment decision-making in pleural effusion cases. In support of its clinical utility, panbacterial qPCR showed excellent diagnostic performance (sensitivity 82%, specificity 95%, PPV 93%, NPV 86%) and strong correlation with shotgun metagenomics, bacterial metataxonomics, and conventional culture (Figure 3).

Many patients are possibly over-treated for suspected PSI, usually with broad-spectrum antimicrobials, without definitive microbial confirmation or knowledge of the underlying infecting pathogen(s). This practice can result in treatment-related adverse events, and may contribute to AMR emergence. However, in this study, we did not identify acquired AMR genes amongst our cohort (Table S1), suggesting that a shift towards narrow-spectrum antimicrobials [8] may be achievable with the routine implementation of bacterial metataxonomics and metagenomics in PSI diagnostics. Such a shift would also contribute towards improved antimicrobial stewardship practices.

Finally, we also compared the performance of conventional culture with molecular tests in a negative control group of patients with pleural effusions from known non-infectious causes (predominantly MPEs). Although most controls were indeed found to have a sterile pleural space, one MPE case cultured *Moraxella osloensis*, which was confirmed by WGS and metagenomics. Furthermore, adeno-associated dependoparvovirus A (considered a non-pathogenic virus) and *Corynebacterium* was also seen in another control patient with MPE by metagenomics and bacterial metataxonomics, respectively. Although specimen or sampling contamination represents the most plausible explanation for these results, a bacterial metataxonomic study suggested that the pleural space of patients with non-infective pleural disease may not be sterile, instead potentially containing unique microbial signatures [25]. Further work in this area is needed.

This study has several recognised limitations. Although the first study to systematically compare performance across these diagnostic methods, we acknowledge the limited sample size. Expanding this proof-of-principle work on a larger scale, and across multiple testing sites, will be important for understanding diagnostic performance and clinical utility of these tests among broader Australian and international cohorts. Secondly, immediate antimicrobial administration upon suspicion of PSI, which often occurs prior to pleural sampling, is required to prevent potential sepsis development; however, this practice may have negatively affected our culture and molecular PSI diagnostic rates. In

particular, our implementation of human DNA depletion prior to metagenomic sequencing may have negatively impacted our ability to detect extracellular microbial DNA [26]. One way to overcome this issue is to perform deeper metagenomic sequencing on total DNA; however, such an approach is more costly, and may increase the risk of missing low-abundance microbes due to the overwhelming human signal [26,27]. Third, increasingly sensitive molecular assays come with the trade-off that microorganism presence might represent either a contaminant or a bona fide pathogen; such false-positive results can be mitigated by exercising strict aseptic practice during specimen collection and processing. Fourth, index hopping and 'kitome' contamination are known drawbacks of next-generation sequencing, especially in low-biomass specimens [27]. However, overcoming these issues by subtracting background signal resulted in 'real' *E. coli* signal (as determined by WGS-confirmed culture) being inadvertently omitted in SCHI0125-P due to higher *E. coli* metagenomic/*Shigella-Escherichia* bacterial metataxonomic reads in the reagent-only controls. One way to reduce this issue might be to employ ultraclean, certified microbe-DNA free reagents [28], although using such reagents represents an added cost. Fifth, 'incorporation bias' [29] should be considered when interpreting the sensitivity/specificity of conventional culture results, given that *in vitro* culture data contribute to the PSI diagnostic 'reference standard', thereby inflating estimates of culture performance in this study design. Finally, we did not assess RNA viruses in this study using e.g. viral-specific qPCRs or metatranscriptomics; their contribution to PSI aetiology in our cohort is therefore unknown.

Conclusion

This real-world prospective study demonstrates the superiority of molecular methods (panbacterial qPCR, bacterial metataxonomics, and shotgun metagenomics) for both PSI diagnosis and aetiology. Based on our findings, we postulate that routine incorporation of molecular tests alongside conventional culture would result in more accurate PSI diagnoses. An important next step will be to determine, via randomised clinical trials, whether same-day panbacterial qPCR testing, followed by high-throughput sequencing methods where required (i.e., bacterial metataxonomics and/or metagenomics), can inform clinical decision-making, aid in antimicrobial stewardship, and improve patient outcomes in suspected PSI.

Conflicts of Interest Statement: The authors declare no conflict of interest. The funders had no role in study design, in the collection, analyses, or interpretation of data, in manuscript writing, or in the decision to publish the results.

Acknowledgements: We thank Emma Seaniger and Louise McIntosh for assistance with sample collection and study coordination, Michael Caffery and the Pathology Queensland laboratory scientists for their assistance with culture, and the Australian BioCommons team (led by Ashley Dungan at University of Melbourne, and Melissa Burke at University of Queensland) for providing QIIME 2 training.

Funding: This work was funded by Wishlist Sunshine Coast Hospital Foundation (award 2021-04-CRG to PTB, TB, OO, JG, DSS, and EPP) and Advance Queensland (awards AQIRF0362018 to EPP and AQIRF095-2020-CV to OSO).

Tables

Table 1. Patient demographic and clinical data

Clinical & Demographic Data						Blood & Serum					Pleural Fluid				Imaging		Procedure		Outcome	PSI Likelihood*
Participant ID†	Age (5-year range)	Gender	immunosuppression	Fever	Intensive care unit admission	Total white cell count (cells x10^9/L)	C-reactive protein (mg/L)	Procalcitonin (µg/L)	Serum LDH (unit/L)	Serum Protein (g/L)	Fluid LDH (unit/L)	Fluid Protein (g/L)	Fluid pH	Fluid Glucose (mmol/L)	Consolidation	Appearance (PSI)/effusion aetiology (non-PSI)	IPE	CTS	30-day mortality	1 – Unlikely 2 – Possible 3 – Definite/Probable
SCHI0123-P	75-80	M	0	1	0	31	414	1.27	251	61	3310	53	6.6	<0.3	1	Complex	1	0	0	3
SCHI0125-P	50-5	F	0	1	1	16	547	0.67	296	68	173	38	-	5.4	1	Complex	1	0	0	3
SCHI0126-P	70-75	M	0	1	1	15.7	191	0.11	183	60	581	34	7.3	9.2	1	Complex	1	0	0	2
SCHI0127-P	35-40	F	0	1	0	15.8	511	3.12	191	60	6920	44	7	<0.3	1	Simple	0	1	0	3
SCHI0128-P	45-50	M	0	1	0	8.4	119	0.11	405	60	280	37	7.4	6.2	0	Simple	0	0	1	2
SCHI0131-P	80-85	M	0	1	1	10.2	39	7.72	201	61	2130	30	-	<0.3	1	Complex	0	1	1	3
SCHI0132-P	20-25	M	0	1	0	12.9	229	1.42	161	68	1550	52	7	2.5	1	Complex	1	0	0	3
SCHI0133-P	25-29	M	0	1	1	27.6	97	0.28	275	70	897	48	6.8	2.4	1	Complex	1	0	0	3
SCHI0134-P	60-65	F	0	1	0	14.4	217	6.29	108	64	856	42	6.8	<0.3	0	Complex	1	0	1	2
SCHI0135-P	70-75	M	0	1	0	13	246	0.99	264	64	514	48	7	3.6	0	Complex	1	0	0	3
SCHI0136-P	90-95	M	0	1	0	33.6	519	0.47	224	76	1680	53	6.6	<0.3	1	Complex	1	0	0	3
SCHI0140-P	30-35	M	0	1	1	24.8	409	9.57	295	52	6210	49	6.9	<0.3	1	Complex	1	1	0	3
SCHI0141-P	90-95	M	0	1	0	14.6	130	0.09	248	59	604	46	7.2	4.9	1	Complex	1	0	0	3
SCHI0143-P	65-70	F	1	1	0	12.1	119	2.13	358	49	874	23	-	3.8	1	Complex	1	0	0	2
SCHI0148-P	40-45	F	0	0	0	8.4	39	0.07	169	65	403	48	7.3	3.3	1	Complex	0	0	0	2
SCHI0149-P	70-75	M	0	0	0	8.5	81	0.05	286	67	1200	46	7.3	3.3	0	Complex	0	0	0	2

SCHI0150-P	75-80	F	1	1	0	20.1	270	4.33	298	56	1110	41	7.3	3.5	1	Complex	1	0	0	2
SCHI0157-P	30-35	M	0	1	0	12.3	99	0.08	169	69	727	58	6.6	<0.3	1	Complex	1	0	0	3
SCHI0158-P	60-65	M	0	1	0	28.5	196	1.47	273	52	539	29	7.2	5.9	0	Complex	0	0	0	3
SCHI0159-P	70-75	F	0	1	0	11.6	135	0.82	477	54	292	29	7.5	6	1	Complex	0	0	0	2
SCHI0160-P	65-70	M	1	1	0	9.5	164	0.54	209	50	313	32	7.4	11.9	1	Complex	1	0	0	2
SCHI0162-P	55-60	M	0	1	0	9	106	0.16	291	65	610	48	-	3.9	1	Complex	1	1	0	2
SCHI0166-P	75-80	M	0	1	0	24.6	414	0.88	220	56	4990	49	6.6	<0.3	0	Complex	1	0	0	3
SCHI0163-P	70-75	M	0	0	0	13.9	245	0.3	145	57	3990	46	7.0	3.5	1	Complex	1	0	0	3
SCHI0169-P	85-90	M	0	1	0	15.2	227	0.17	171	71	490	53	-	6.1	1	Complex	0	0	0	3
SCHI0172-P	20-25	M	0	1	1	16.4	171	0.17	110	49	17400	28	-	<0.3	1	Complex	0	0	0	3
SCHI0151-C	70-75	F	0	0	0	10.5	83	0.14	236	62	393	45	7.3	10	0	MPE	0	0	NA	1
SCHI0152-C	80-85	M	0	0	0	10.3	90	0.19	160	62	81	39	7.3	4.9	0	MPE	0	0	NA	1
SCHI0161-C	85-90	M	0	0	0	10.5	26	0.11	172	72	232	41	7.3	7.9	0	MPE	0	0	NA	1
SCHI0164-C	75-80	M	0	0	0	5.2	124	-	250	62	427	37	7.3	4.6	0	MPE	0	0	NA	1
SCHI0165-C	80-85	F	0	0	0	15.2	29	0.26	194	72	99	39	7.4	6	0	CCF	0	0	NA	1
SCHI0168-C	40-45	M	0	0	0	9.6	7.3	-	287	45	287	45	7.4	5.2	0	MPE	0	0	NA	1
SCHI0170-C	60-65	M	0	0	0	4.5	-	-	182	-	91	46	7.5	7.8	0	MPE	0	0	NA	1
SCHI0173-C	70-75	M	0	0	0	6.9	84	-	391	61	672	39	7.4	6.3	0	MPE	0	0	NA	1
SCHI0174-C	75-80	M	1	0	0	6.7	-	-	222	67	245	44	-	9.2	0	MPE	0	0	NA	1
SCHI0175-C	85-90	M	0	0	0	4.3	5	-	193	70	88	45	-	6.2	0	MPE	0	0	NA	1

Abbreviations*:* CCF, Congestive Cardiac Failure; C-reactive protein (CRP); CTS, Cardiothoracic Surgical decortication; IPE, Intrapleural Enzyme therapy; MPE, Malignant Pleural Effusion; SIRS, Systemic Inflammatory Response Syndrome; LDH, Lactate dehydrogenase. 0=no, 1=yes.

[†]The -P suffix denotes participants suspected of having a PSI, whereas the -C suffix denotes non-PSI patients (i.e. negative controls).

* i) *Definite or probable PSI:* Gram stain and/or culture positive on pleural fluid; or pleural fluid pH < 7.2 and 2 or more of the following: serum CRP > 100 mg/L; complex pleural fluid on imaging; fever (> 38.0^{o}C); ii) *Possible PSI:* gram stain or culture negative with pH > 7.2 and 2 or more of the following: CRP > 100 mg/L; complex pleural fluid on imaging; fever (> 38.0 ^{o}C); or iii) *Unlikely PSI:* gram stain or culture negative with pH > 7.2, CRP < 100 mg/L, no fever, simple effusion and an alternate diagnoses confirmed (i.e. heart failure, malignancy).

Table 2. Pleural space infection (PSI) diagnostic performance across 26 PSI diagnosed participants and 10 controls with a diagnosed non-PSI aetiology

Participant ID	Metagenomic result[#]	Bacterial metataxonomic result[†]	Culture result, Research Lab (WGS result)	Culture result, Pathology Lab (MALDI-TOF result)	Panbacterial qPCR[‡]
Diagnosed with PSI					
SCHI0123-P	Polymicrobial (*Fusobacterium nucleatum*, *Fusobacterium hwasookii*, *Staphylococcus* phage Andhra, *Prevotella loescheii*, *Rothia mucilaginosa*, *Enterococcus faecium*, *Fusobacterium* sp. oral taxon 203)	Monomicrobial (*Fusobacterium*)	NG	NG	Yes (C_T=20.8)
SCHI0125-P	Polymicrobial (*Staphylococcus* phage Andhra, *Prevotella oris, Enterococcus faecium*, *Streptococcus mitis*, *Streptococcus anginosus*, ***Escherichia coli***[a], *Streptococcus pneumoniae, Fonsecaea pedrosoi*, *Candida tropicalis, Pyricularia pennisetigena*, ***Staphylococcus aureus***[b])	Monomicrobial (*Prevotella*)	***Escherichia coli**, *Staphylococcus saprophyticus****	*Escherichia coli*	Yes (C_T=25.7)
SCHI0126-P	ND	ND	NG	NG	No (C_T=33.9)
SCHI0127-P	Polymicrobial (*Streptococcus pyogenes*, *Staphylococcus* phage Andhra, *Streptococcus dysgalactiae*, *Streptococcus agalactiae*, *Enterococcus faecium*, *Rothia mucilaginosa*)	Monomicrobial (*Streptococcus*)	Positive (not characterised)	*Streptococcus pyogenes*	Yes (C_T=27.5)
SCHI0128-P	Polymicrobial (*Klebsiella pneumoniae*, *Staphylococcus* phage Andhra, *Mycoplasma hyorhinis*, *Carnobacterium divergens*, *Actinomyces odontolyticus*, *Rothia mucilaginosa*, *Streptococcus mitis*, *Haemophilus parainfluenzae*, *Enterococcus faecium*, *Streptococcus parasanguinis*, *Staphylococcus aureus*)	ND	NG	NG	No (C_T=35.3)

SCHI0131-P[e]	Polymicrobial (*Streptococcus mitis*, *Streptococcus anginosus*, *Streptococcus pneumoniae*, *Streptococcus* sp. oral taxon 431, *Streptococcus oralis*, *Streptococcus salivarius*, *Gemella haemolysans*, *Streptococcus pseudopneumoniae*, *Streptococcus* sp. ChDC B345, *Streptococcus gordonii*, *Streptococcus parasanguinis, Streptococcus cristatus, Streptococcus* sp. HSISM1, *Streptococcus australis, Streptococcus* sp. oral taxon 064, *Streptococcus* sp. FDAARGOS_192, *Streptococcus intermedius, Streptococcus* sp. A12, *Veillonella atypica*, *Actinomyces odontolyticus*, *Streptococcus sanguinis*, *Gemella sanguinis*, *Streptococcus thermophilus*, *Capnocytophaga leadbetteri*, *Streptococcus equinus*, *Streptococcus viridans*, *Rothia dentocariosa*, *Capnocytophaga gingivalis*, *Veillonella parvula, Rothia mucilaginosa, Streptococcus vestibularis, Streptococcus* sp. HSISS2, *Prevotella jejuni, Streptococcus constellatus, Streptococcus* sp. I-P16, *Streptococcus* sp. I-G2, *Veillonella dispar, Bifidobacterium longum, Streptococcus* sp. HSISS3, *Gemella morbillorum*, *Haemophilus influenzae*, *Streptococcus* sp. HSISS1, *Atopobium parvulum*, *Streptococcus dysgalactiae*, *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Staphylococcus aureus, Prevotella salivae, Prevotella melaninogenica, Tannerella* sp. oral taxon HOT-286, *Actinomyces* sp. oral taxon 171, *Actinomyces oris, Capnocytophaga sputigena, Haemophilus parainfluenzae, Neisseria subflava, Campylobacter showae, Streptococcus* phage SM1, *Streptococcus mutans, Streptococcus sobrinus, Streptococcus acidominimus, Lactococcus lactis, Lachnospiraceae* bacterium oral taxon 500, *Actinomyces naeslundii, Actinomyces viscosus, Capnocytophaga* sp. oral taxon 878, *Neisseria elongata*, *Lautropia mirabilis*, *Fusobacterium periodonticum*, *Fusobacterium nucleatum*, *Streptococcus ratti*, **>70 additional taxa**[c])	Polymicrobial (*Streptococcus*, *Streptococcus anginosus*, *Granulicatella*, *Streptococcus salivarius*, *Gemella*, *Prevotella jejuni*, *Veillonella*, *Streptococcus constellatus*, *Prevotella melaninogenica*; *Neisseria perflava*, *Neisseria*, *Fusobacterium periodonticum*, *Prevotella salivae*, *Haemophilus influenzae*, *Leptotrichia*, *Capnocytophaga gingivalis*, *Capnocytophaga leadbetteri*, *Schaalia odontolytica*, *Neisseria elongata*, *Atopobium*, *Fusobacterium*, *Porphyromonas*, *Bergeyella*, *Leptotrichia hongkongensis*, *Oribacterium*, *Lautropia*, *Oribacterium*, *Selenomonas artemidis*, *Stomatobaculum*, *Haemophilus*, *Prevotella shahii*, *Rothia*)	***Pichia kudriavzevii****	*Pichia kudriavzveii*; enteric & mixed anaerobic bacteria	Yes (C_T=17.7)
SCHI0132-P	Monomicrobial (***Staphylococcus aureus***[b])	Monomicrobial (***Streptococcus***[d])	Positive (not characterised)	Coagulase-negative *Staphylococcus* sp.	No (C_T=33.5)
SCHI0133-P	ND	ND	NG	NG	No (C_T=33.9)
SCHI0134-P	Monomicrobial (*Klebsiella pneumoniae*)	Monomicrobial (*Klebsiella*)	NG	*Klebsiella pneumoniae*	Yes (C_T=23.5)
SCHI0135-P	ND	ND	NG	NG	No (C_T=34.5)
SCHI0136-P	Monomicrobial (*Streptococcus intermedius*)	ND	NG	*Streptococcus intermedius*	Yes (C_T=27.5)
SCHI0140-P	Polymicrobial (*Streptococcus pyogenes*, *Streptococcus dysgalactiae*, *Candida dubliniensis*)	Polymicrobial (*Streptococcus, Streptococcus pyogenes*)	NG	*Streptococcus pyogenes*, *Staphylococcus aureus*	Yes (C_T=25.2)
SCHI0141-P	ND	ND	NG	NG	No (C_T=33.5)
SCHI0143-P	Monomicrobial (*Staphylococcus saprophyticus*)	Monomicrobial (***Streptococcus***[d])	NG	NG	Yes (C_T=30.1)
SCHI0148-P	ND	ND	NG	NG	No (C_T=34.6)
SCHI0149-P	ND	ND	NG	NG	No (C_T=31.3)
SCHI0150-P	ND	Monomicrobial (*Haemophilus*)	NG	NG	Yes (C_T=28.1)
SCHI0157-P	Monomicrobial (*Streptococcus intermedius*)	Monomicrobial (*Streptococcus*)	NG	*Streptococcus intermedius*	Yes (C_T=24.2)
SCHI0158-P	ND	Polymicrobial (*Fusobacterium*, *Parvimonas*, *Eubacterium*)	NG	NG	Yes (C_T=29.2)

SCHI0159-P	ND	ND	NG	NG	No (C_T=32.6)
SCHI0160-P	ND	ND	NG	NG	No (C_T=32.3)
SCHI0162-P	ND	ND	NG	NG	No (C_T=31.2)
SCHI0163-P	Monomicrobial (*Haemophilus parainfluenzae*)	Polymicrobial (*Haemophilus*, *Novosphingobium*)	NG	NG	Yes (C_T=23.5)
SCHI0166-P	Monomicrobial (*Escherichia coli*)	Monomicrobial (*Escherichia-Shigella*)	Positive (not characterised)	*Escherichia coli*	Yes (C_T=21.5)
SCHI0169-P	ND	ND	NG	NG	No (C_T=33.2)
SCHI0172-P	Polymicrobial (*Prevotella pleuritidis*, *Fusobacterium nucleatum*, *Prevotella enoeca*, *Prevotella intermedia*, *Hallela seregens*, *Porphyromonas gingivalis*, *Tannerella forsythia*, *Prevotella buccae*, *Prevotella oris*, *Fusobacterium* sp. oral taxon 203, *Prevotella nigrescens*, *Prevotella denticola*, *Streptococcus pyogenes*, *Prevotella veroralis*, *Fusobacterium hwasookii*, *Prevotella aurantiaca, Bacteroides fragilis*, *Bacteroides heparinolyticus*, *Prevotella salivae*, *Prevotella fusca*, *Prevotella pallens*, *Prevotella nanceiensis*, *Prevotella jejuni*, *Prevotella oulorum*, *Prevotella maculosa*, *Prevotella bivia*, *Prevotella melaninogenica*, *Prevotella micans*, *Prevotella amnii*, *Prevotella conceptionensis*, *Enterococcus faecium*)	Polymicrobial (*Enterococcus*, *Prevotella pleuritidis*)	Positive (not characterised)	*Fusobacterium nucleatum*	Yes (C_T=20.3)
Diagnosed with non-PSI (Negative Controls)					
SCHI0151-C	ND	ND	NG	NG	No (C_T=32.7)
SCHI0152-C	ND	Monomicrobial (*Escherichia-Shigella*)	***Candida parapsilosis****	NG	No (C_T=35.7)
SCHI0161-C	ND	ND	NG	NG	No (C_T=36.7)
SCHI0164-C	ND	ND	NG	NG	No (C_T=35.9)
SCHI0165-C	ND	ND	NG	NG	No (C_T=32.3)
SCHI0168-C	ND	ND	NG	NG	No (C_T=32.7)
SCHI0170-C	ND	ND	NG	NG	No (C_T=38.7)
SCHI0173-C	Monomicrobial (Adeno-associated dependoparvovirus A)	Monomicrobial (*Corynebacterium*)	NG	NG	No (C_T=31.3)
SCHI0174-C	ND	ND	NG	NG	Yes (C_T=30.9)
SCHI0175-C	Monomicrobial (*Moraxella osloensis*)	ND	***Moraxella osloensis****	NG	No (C_T=31.9)

Abbreviations: C_T, cycles-to-threshold; MALDI-TOF, matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry; ND, not determined; NG, no growth; PE, pleural effusion. Salmon-coloured cells denote possible false-negative results in the PSI cohort.
Bolded text denotes footnoted item; gray-shaded fields indicate discordant negative pleural space infection diagnosis.
[#]Minimum read threshold of ≥400 reads
[†]Minimum read threshold of ≥40 reads
[‡]Based on TRIzol interphase DNA extraction
*Cultures subjected to whole-genome sequencing
[a]*Escherichia coli* excluded from the metagenomic output due to its read count being lower than the background (contaminant) signal
[b]No *S. saprophyticus* or other coagulase-negative staphylococci were identified, suggesting either taxonomic misassignment or a detection limit issue
[c]*Pichia kudriavzevii* identified in the metagenome data (1963 reads)
[d]Probable taxonomic misassignment of certain '*Staphylococcus*' as '*Streptococcus*' using bacterial metataxonomics
[e]SCHI0131-P, yielded exceptionally high and diverse microbial burden across all testing methods; this case differed clinically from others in that the participant had suffered a ruptured oesophagus (Boerhaave syndrome)

Table 3. Comparative diagnostic accuracy of conventional culture and molecular methods for detecting pleural space infection (PSI) when compared to a surrogate gold-standard PSI classification of 'definite or probable PSI'*.

	Conventional culture	Panbacterial qPCR	Bacterial metataxonomics	Metagenomics	Combined molecular
% Sensitivity (95% CI)	70.6 (44.0-89.7)	82.4 (56.6-96.2)	88.2 (63.6-98.5)	82.4 (56.6-96.2)	100 (80.5-100)
% Specificity (95% CI)	100 (82.3-100)	94.7 (74.0-99.9)	94.7 (74.0-99.9)	89.5 (66.9-98.7)	84.2 (60.4-96.6)
% PPV (95% CI)	100 (73.5-100)	93.3 (68.1-99.8)	93.8 (69.8-99.8)	87.5 (61.7-98.4)	85 (62.1-96.8)
% NPV (95% CI)	79.2 (57.8-92.9)	85.7 (63.7-97.0)	90 (68.3-98.8)	85 (62.1-96.8)	100 (79.4-100)

Abbreviations: CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value; qPCR, quantitative PCR; Combined Molecular, all molecular methods (qPCR, bacterial metataxonomics, metagenomics). ***** *Definite/Probable PSI:* Gram stain and/or culture positive on pleural fluid; or pleural fluid pH < 7.2 and 2 or more of the following: serum C-reactive protein > 100 mg/L; complex pleural fluid on imaging; fever (> 38°C)

Figure legends

Figure 1. Bar graph depicting metagenomic profiles identified from 26 suspected pleural space infection specimens and 10 control cohort specimens. *Conventional culture positive; ^16S ribosomal RNA (panbacterial) quantitative PCR positive; #Whole-genome sequencing-confirmed (from culture). Dominant taxa are labelled on each bar.

Figure 2. Bar graph depicting bacterial 16S ribosomal RNA (rRNA) metataxonomic profiles identified from 26 suspected pleural space infection specimens and 10 control cohort specimens. *Conventional culture positive; ^16S ribosomal RNA (panbacterial) quantitative PCR positive; #Whole-genome sequencing result from culture; ‡Likely incorrect assignment of *Staphylococcus* as *Streptococcus* (1 case confirmed as a coagulase-negative *Staphylococcus* by MALDI-TOF analysis of culture). Dominant taxa are labelled on each bar.

Figure 3. Correlation matrix of the four pleural space infection (PSI) diagnostic methods used in this study. 1=perfect correlation; -1=no correlation. Conventional culture showed the weakest correlation when compared with each of the three molecular methods, an expected result due to known PSI underdiagnosis using this method [5-8].

References

1. Bedawi EO, Guinde J, Rahman NM, Astoul P. Advances in pleural infection and malignancy. European Respiratory Review 2021;30:200002.
2. Cargill TN, Hassan M, Corcoran JP, et al. A systematic review of comorbidities and outcomes of adult patients with pleural infection. European Respiratory Journal 2019;54:1900541.
3. Brims F, Popowicz N, Rosenstengel A, et al. Bacteriology and clinical outcomes of patients with culture-positive pleural infection in Western Australia: A 6-year analysis. Respirology 2019;24:171-8.
4. Bedawi EO, Ricciardi S, Hassan M, et al. ERS/ESTS statement on the management of pleural infection in adults. European Respiratory Journal 2022:2201062.
5. Maskell NA, Batt S, Hedley EL, Davies CW, Gillespie SH, Davies RJ. The bacteriology of pleural infection by genetic and standard methods and its mortality significance. Am J Respir Crit Care Med 2006;174:817-23.
6. Rahman NM, Maskell NA, West A, et al. Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural Infection. New England Journal of Medicine 2011;365:518-26.
7. Shiraishi Y, Kryukov K, Tomomatsu K, et al. Diagnosis of pleural empyema/parapneumonic effusion by next-generation sequencing. Infect Dis (Lond) 2021;53:450-9.
8. Kanellakis NI, Wrightson JM, Gerry S, et al. The bacteriology of pleural infection (TORPIDS): an exploratory metagenomics analysis through next generation sequencing. The Lancet Microbe 2022;3:e294-e302.
9. Boyanova L, Vladimir D, Gergova G, et al. Anaerobic microbiology in 198 cases of pleural empyema: a Bulgarian study. Anaerobe 2004;10:261-7.
10. Corcoran JP, Wrightson JM, Belcher E, DeCamp MM, Feller-Kopman D, Rahman NM. Pleural infection: past, present, and future directions. Lancet Respir Med 2015;3:563-77.
11. Schlaberg R, Chiu CY, Miller S, Procop GW, Weinstock G. Validation of Metagenomic Next-Generation Sequencing Tests for Universal Pathogen Detection. Arch Pathol Lab Med 2017;141:776-86.
12. Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. Microbiome 2015;3:31.
13. Hilton SK, Castro-Nallar E, Pérez-Losada M, et al. Metataxonomic and Metagenomic Approaches vs. Culture-Based Techniques for Clinical Pathology. Front Microbiol 2016;7:484.
14. Dyrhovden R, Nygaard RM, Patel R, Ulvestad E, Kommedal Ø. The bacterial aetiology of pleural empyema. A descriptive and comparative metagenomic study. Clin Microbiol Infect 2019;25:981-6.
15. Xu H, Hu X, Wang W, et al. Clinical Application and Evaluation of Metagenomic Next-Generation Sequencing in Pulmonary Infection with Pleural Effusion. Infect Drug Resist 2022;15:2813-24.
16. Madden DE, Olagoke O, Baird T, et al. Express yourself: quantitative real-time PCR assays for rapid chromosomal antimicrobial resistance detection in *Pseudomonas aeruginosa*. Antimicrob Agents Chemother 2022;66:e0020422.

17. Herlemann DP, Labrenz M, Jurgens K, Bertilsson S, Waniek JJ, Andersson AF. Transitions in bacterial communities along the 2000 km salinity gradient of the Baltic Sea. ISME J 2011;5:1571-9.
18. Nadkarni MA, Martin FE, Jacques NA, Hunter N. Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology (Reading) 2002;148:257-66.
19. Ahmadi B, Hashemi SJ, Zaini F, et al. A case of onychomycosis caused by Aspergillus candidus. Med Mycol Case Rep 2012;1:45-8.
20. Klaassen CH, Jeunink MA, Prinsen CF, et al. Quantification of human DNA in feces as a diagnostic test for the presence of colorectal cancer. Clin Chem 2003;49:1185-7.
21. Light RW, Macgregor MI, Luchsinger PC, Ball WC, Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 1972;77:507-13.
22. Nguyen S, Baker K, Padman BS, et al. Bacteriophage transcytosis provides a mechanism To cross epithelial cell layers. mBio 2017;8.
23. Brown-Jaque M, Muniesa M, Navarro F. Bacteriophages in clinical samples can interfere with microbiological diagnostic tools. Sci Rep 2016;6:33000.
24. Franchetti L, Schumann DM, Tamm M, Jahn K, Stolz D. Multiplex bacterial polymerase chain reaction in a cohort of patients with pleural effusion. BMC Infect Dis 2020;20:99.
25. Kwok B, Wu BG, Kocak IF, et al. Pleural fluid microbiota as a biomarker for malignancy and prognosis. Sci Rep 2023;13:2229.
26. Nelson MT, Pope CE, Marsh RL, et al. Human and extracellular DNA depletion for metagenomic analysis of complex clinical infection samples yields optimized viable microbiome profiles. Cell Rep 2019;26:2227-40.e5.
27. Salter SJ, Cox MJ, Turek EM, et al. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC Biol 2014;12:87.
28. Quince C, Walker AW, Simpson JT, Loman NJ, Segata N. Shotgun metagenomics, from sampling to analysis. Nat Biotechnol 2017;35:833-44.
29. Kea B, Hall MK, Wang R. Recognising bias in studies of diagnostic tests part 2: interpreting and verifying the index test. Emerg Med J 2019;36:501-5.


PSI cohort
Control cohort
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Fusobacterium nucleatum
Stapn phage
P. oris
Streptococcus pyogenes
S. phage
Kpn
S. mitis
Staphylococcus aureus
Kpn
Streptococcus intermedius
Streptococcus pyogenes
Staphylococcus saprophyticus
Streptococcus intermedius
Haemophilus parainfluenzae
E. coli
Prevotella pleuritidus
Adeno-dependovirus A
Moraxella osloensis
^SCHI0123-P
^*SCHI0125-P
SCHI0126-P
^*SCHI0127-P
SCHI0128-P
^*SCHI0131-P
*SCHI0132-P
SCHI0133-P
^*SCHI0134-P
SCHI0135-P
^*SCHI0136-P
^*SCHI0140-P
SCHI0141-P
^SCHI0143-P
SCHI0148-P
SCHI0149-P
^SCHI0150-P
^*SCHI0157-P
^SCHI0158-P
SCHI0159-P
SCHI0160-P
SCHI0162-P
^SCHI0163-P
^*SCHI0166-P
SCHI0169-P
^*SCHI0172-P
SCHI0151-C
*SCHI0152-C
SCHI0161-C
SCHI0164-C
SCHI0165-C
SCHI0168-C
SCHI0170-C
SCHI0173-C
^SCHI0174-C
#*SCHI0175-C
Fusobacterium nucleatum
Staphylococcus phage Andhra
Prevotella oris
Streptococcus mitis
Streptococcus anginosus
Streptococcus pneumoniae
Enterococcus faecium
Streptococcus pyogenes
Prevotella pleuritidis
Klebsiella pneumoniae
Staphylococcus aureus
Mycoplasma hyorhinis
Streptococcus sp. oral taxon 431
Streptococcus oralis
Staphylococcus saprophyticus
Prevotella enoeca
Streptococcus salivarius
Gemella haemolysans
Rothia mucilaginosa
Streptococcus pseudopneumoniae
Streptococcus sp. ChDC B345
Prevotella intermedia
Streptococcus gordonii
Streptococcus parasanguinis
Streptococcus intermedius
Actinomyces odontolyticus
Carnobacterium divergens
Candida dubliniensis
Fusobacterium hwasookii
Streptococcus cristatus
Haemophilus parainfluenzae
Streptococcus sp. HSISM1
Streptococcus australis
Streptococcus sp. oral taxon 064
[Hallella] seregens
Streptococcus sp. FDAARGOS_192
Streptococcus dysgalactiae
Prevotella loescheii
Porphyromonas gingivalis
Streptococcus sp. A12
Fusobacterium sp. oral taxon 203
Adeno-associated dependoparvovirus A
Veillonella atypica
Escherichia coli
Streptococcus sanguinis
Streptococcus agalactiae
Gemella sanguinis
Tannerella forsythia
Capnocytophaga leadbetteri
Streptococcus thermophilus
Streptococcus equinus
Streptococcus viridans
Prevotella buccae
Rothia dentocariosa
Moraxella osloensis
Capnocytophaga gingivalis
Prevotella jejuni


PSI cohort
Control cohort
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Fusobacterium
Prevotella
Streptococcus
Streptococcus
Streptococcus
Klebsiella
Streptococcus
Streptococcus
Haemophilus
Streptococcus
Fusobacterium
Haemophilus
Escherichia-Shigella
Enterococcus
P. pleuritidis
Escherichia-Shigella
Cloacibacterium
^SCHI0123-P
^*SCHI0125-P
SCHI0126-P
^*SCHI0127-P
SCHI0128-P
^*SCHI0131-P
‡*SCHI0132-P
SCHI0133-P
^*SCHI0134-P
SCHI0135-P
^*SCHI0136-P
^*SCHI0140-P
SCHI0141-P
‡^SCHI0143-P
SCHI0148-P
SCHI0149-P
^SCHI0150-P
^*SCHI0157-P
^SCHI0158-P
SCHI0159-P
SCHI0160-P
SCHI0162-P
^SCHI0163-P
^*SCHI0166-P
SCHI0169-P
^*SCHI0172-P
SCHI0151-C
*SCHI0152-C
SCHI0161-C
SCHI0164-C
SCHI0165-C
SCHI0168-C
SCHI0170-C
SCHI0173-C
^SCHI0174-C
*SCHI0175-C
Fusobacterium
Prevotella
Streptococcus
Streptococcus anginosus
Streptococcus salivarius
Streptococcus constellatus
Streptococcus pyogenes
Klebsiella
Escherichia-Shigella
Granulicatella
Gemella
Prevotella jejuni
Prevotella melaninogenica
Prevotella salivae
Prevotella pleuritidis
Prevotella shahii
Veillonella
Haemophilus
Parvimonas
Haemophilus influenzae
Neisseria
Neisseria perflava
Neisseria elongata
Cloacibacterium
Fusobacterium periodonticum
Novosphingobium
Corynebacterium
Leptotrichia
Capnocytophaga gingivalis
Capnocytophaga leadbetteri
Enterococcus
Schaalia odontolytica
[Eubacterium] brachy
Atopobium
Porphyromonas
Bergeyella
Leptotrichia hongkongensis
Lautropia
Oribacterium
Selenomonas artemidis
Stomatobaculum
Rothia

	Metagenomics	Metataxonomics	Panbacterial qPCR	Culture
Metagenomics	1	0.69	0.69	0.56
Metataxonomics		1	0.85	0.39
Panbacterial qPCR			1	0.39
Culture				1

Spearman's rho (r_S)

1
0.8
0.6
0.4
0.2
0